Diabetes Mellitus, Type 2, Gestational Diabetes Mellitus, Pre-diabetes
Conditions
Keywords
Diabetes Prevention, Shared Decision Making
Brief summary
Our goal is to test whether shared decision making for diabetes prevention can help women with a history of gestational diabetes mellitus (GDM) who are at high risk of developing type 2 diabetes (T2DM) increase weight loss and adoption of evidence based strategies to lower their risk of incident diabetes.
Detailed description
Women with a history of gestational diabetes mellitus (GDM) are at high risk of developing type 2 diabetes (T2DM) but evidence from the Diabetes Prevention Program (DPP) indicates that lifestyle change and metformin use in this population are clinically equivalent, each reducing the incidence of T2DM by approximately 50%. Shared decision making (SDM) is an attractive approach in this situation where several options are available. We can use a decision aid to make the decision explicit, describe the available options with equipoise, elicit patient preferences, and help patients make an informed decision that is right for them. There are no existing studies evaluating SDM for diabetes prevention among women with a history of GDM. Therefore, this study aims to test the effectiveness of an RCT evaluating SDM for diabetes prevention on weight loss among overweight/obese women with a history of GDM and hemoglobin A1c between 5.7-6.4%, as well as uptake of lifestyle change and/or metformin use and other patient-reported outcomes (e.g., physical activity, eating patterns, patient activation, health-related quality of life). The study will recruit 310 patients from two large health care systems (n=155 from UCLA Health and n=155 from Intermountain Healthcare) who will be randomized to either usual care or in-person shared decision making for diabetes prevention.
Interventions
BEHAVIORALShared decision-making for diabetes prevention
Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
Sponsors
Intermountain Health Care, Inc.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of California, Los Angeles
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 54 Years
Healthy volunteers
Yes
Inclusion criteria
* 18 years to 54 (Adult) * Females * Most recent BMI ≥25 kg/m2 (or \>23 if Asian American) * History of gestational diabetes mellitus based on: * Diagnostic code ICD10 or 1-hour glucose challenge test \> 140 mg/dL, followed by 3-hour glucose tolerance test with TWO or more values. Cut-offs \>= i. 95 at 0-hour ii. 180 at 1-hour iii. 155 at 2-hour iv. 140 at 3-hour * History of prediabetes in prior 36 months defined by either 1. most recent HbA1c 5.7-6.4% or 2. most recent FPG 100-125 mg/dL or 3. prior diabetes diagnostic codes + abnormal labs * Patient at UCLA or Intermountain Healthcare Systems with provider visit or labs in prior 12 months
Exclusion criteria
* Delivery within the last 12 months at randomization * History of diabetes (i.e., prior HbA1c 6.5% or above, or 2 or more fasting plasma glucose 125 or above, or prior diagnostic code) * Any anti-glycemic medications or insulin use 12 months prior to randomization * Most recent eGFR \<45 ml/min * BMI \>60 kg/m2 at randomization * History of any type of weight loss surgery 12 months prior to randomization * Currently being treated for an eating disorder, such as anorexia or bulimia * Currently pregnant or planning to get pregnant in the next 12 months * Completed a prior prediabetes SDM consult anytime * Currently enrolled OR have ever participated in any CDC certified Diabetes Prevention Program (DPP) * Inability or concerns about doing \>150 minutes of physical activity per week Currently taking a medication called metformin or have been prescribed metformin in the last 12-months * History of metformin intolerance * Unable to attend 3 virtual or in-person visits over the next 2 years at UCLA or Intermountain Healthcare * Non-English primary language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight change | 12 months | Proportion with \>5% weight loss |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Weight Change | 24 months | Proportion with \>5% weight loss |
| Uptake of DPP lifestyle program or metformin | 6 months | 1\) Attending at least 9 of 16 of weekly lifestyle change sessions OR 2) Taking metformin (yes/no) |
| Health-related quality of life | 6, 12, and 24 months | Short-form (SF-36) measure |
Countries
United States
Outcome results
None listed